Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2008 1
2009 1
2010 2
2011 2
2014 1
2019 1
2020 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Ungaro RC, et al. Among authors: gubonina i. Gastroenterology. 2020 Jul;159(1):139-147. doi: 10.1053/j.gastro.2020.03.039. Epub 2020 Mar 26. Gastroenterology. 2020. PMID: 32224129 Free PMC article. Clinical Trial.
[Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians].
Simanenkov VI, Maev IV, Tkacheva ON, Alekseenko SA, Andreev D, Bakulina NV, Bakulin IG, Bordin DS, Vlasov TD, Vorobyeva NM, Grinevich VB, Gubonina IV, Drobizhev MY, Efremov NS, Karateev AE, Kotovskaya YV, Kravchuk I, Krivoborodov GG, Kulchavenya EV, Lila AM, Maevskaya MV, Nekrasova AS, Poluektova EA, Popkova TV, Sablin OA, Solovyeva OI, Suvorov AN, Tarasova GN, Trukhan DI, Fedotova AV. Simanenkov VI, et al. Among authors: gubonina iv. Ter Arkh. 2022 Oct 12;94(8):940-956. doi: 10.26442/00403660.2022.08.201523. Ter Arkh. 2022. PMID: 36286974 Russian.
A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.
Ghosh S, Sensky T, Casellas F, Rioux LC, Ahmad T, Márquez JR, Vanasek T, Gubonina I, Sezgin O, Ardizzone S, Kligys K, Petersson J, Suzuki Y, Peyrin-Biroulet L. Ghosh S, et al. Among authors: gubonina i. J Crohns Colitis. 2020 Jul 29;15(2):228-37. doi: 10.1093/ecco-jcc/jjaa159. Online ahead of print. J Crohns Colitis. 2020. PMID: 32722760 Free PMC article.
[Biliary dysfunction in obese children].
Aleshina EI, Gubonina IV, Novikova VP, Vigurskaia MIu. Aleshina EI, et al. Among authors: gubonina iv. Eksp Klin Gastroenterol. 2014;(8):11-5. Eksp Klin Gastroenterol. 2014. PMID: 25911906 Russian.
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group. Kruis W, et al. Gut. 2009 Feb;58(2):233-40. doi: 10.1136/gut.2008.154302. Epub 2008 Oct 2. Gut. 2009. PMID: 18832520 Free PMC article. Clinical Trial.
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Kruis W, et al. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22. doi: 10.1111/j.1365-2036.2010.04537.x. Epub 2010 Dec 8. Aliment Pharmacol Ther. 2011. PMID: 21138455 Free article. Clinical Trial.
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R; International BUC-57 Study Group. Gross V, et al. J Crohns Colitis. 2011 Apr;5(2):129-38. doi: 10.1016/j.crohns.2010.11.006. Epub 2010 Dec 14. J Crohns Colitis. 2011. PMID: 21453882 Clinical Trial.
12 results